Practo, founded in 2008 by Shashank ND, is a Bengaluru-based health-tech platform revolutionizing how patients access and manage healthcare services. With a mission to make quality healthcare accessible, Practo offers a comprehensive suite of solutions including online consultations, appointment bookings, telemedicine, digital health records, and integrated practice management software for healthcare providers. Over the years, the company has expanded its footprint across multiple countries, connecting millions of patients with trusted doctors and clinics. By leveraging advanced data analytics, AI-driven diagnostics, and seamless user experiences, Practo enhances care coordination, reduces waiting times, and supports preventive health. The platform also empowers healthcare practitioners with tools for efficient practice management, patient engagement, and revenue optimization. Supported by investors like Matrix Partners, Accel, Tencent, and Peak XV, Practo has raised significant funding to innovate its product offerings and grow its operations. As the digital health landscape evolves, Practo continues to focus on building robust technology, expanding telehealth capabilities, and exploring new markets, aiming to deliver holistic healthcare experiences while driving sustained growth and preparing for future milestones such as an eventual IPO.
Founding year | 2008 |
---|---|
Headquarters | Bengaluru, Karnataka, India |
Valuation | ~$418M (2022); aiming higher pre-IPO |
Total Funding | ~$228M over multiple rounds |
Employees | ~1,700 (FY24) |
Annual Revenue (INR) | ₹240 Cr (FY24) |
Annual Net Loss (INR) | ₹17 Cr loss (FY24) |
EBITDA Margin | ~0% (break-even in Q4 FY24) |
Round | Date | Amount | Valuation | Investors |
---|---|---|---|---|
Series A | Mar 2013 | Undisclosed | Not disclosed | Matrix Partners, Accel |
Series B | Jan 2015 | $10M | ~$100M+ | Peak XV Partners, Matrix |
Series C | Aug 2017 | $55M | ~$300M | Peak XV, Tencent |
Series D | Jun 2020 | $60M | ~$418M | Tencent, Peak XV, Z47 |
Debt/Secondary | 2024 | $15M debt | Not disclosed | Existing investors |
Practo’s revenue rose from ₹160 Cr in FY22 to ₹194.5 Cr in FY23 (↑21.5%) and to ₹240 Cr in FY24 (↑23.4%), while net loss narrowed from ₹80 Cr in FY22 to ₹99 Cr in FY23 and to ₹17 Cr in FY24, reflecting improved unit economics and focus on core services.
Practo’s EBITDA improved from ~-50% in FY22 to ~-40% in FY23 and reached break-even by Q4 FY24, driven by operational optimizations and reduced marketing spend.
Employee count increased from ~1,000 in FY22 to ~1,500 in FY23 and ~1,700 in FY24 to support product development, market expansion, and platform operations. Continued hiring focuses on tech, data science, and healthcare partnerships to sustain growth.
In FY24, Practo reported ₹240 Cr revenue (↑23.4% YoY) and narrowed net loss to ₹17 Cr, achieving adjusted EBITDA break-even in Q4 FY24. The company is focusing on sustained profitability, expanding telehealth services, and exploring pre-IPO options while deepening integration with healthcare ecosystems.
Metric | Details |
---|---|
Employees | 1000 → 1500 → 1700 |
Revenue | ₹160 Cr → ₹194.5 Cr (↑21.5%) → ₹240 Cr (↑23.4%) |
Net Loss | ₹80 Cr → ₹99 Cr → ₹17 Cr |
EBITDA Margin | -50% → -40% → 0% |
Valuation & Funding | ~$418M valuation; ~$228M funding |
IPO Status | Preparing for pre-IPO; targeting IPO post-sustained profitability. |
Expansion Focus | Telehealth expansion, AI-driven diagnostics, international markets, adjacent services. |
Latest News | ₹240 Cr revenue, ₹17 Cr loss FY24; EBITDA break-even Q4 and pre-IPO plans |
Practo’s solid revenue growth and rapid loss reduction underscore its leadership in digital healthcare. Focusing on platform efficiencies, telehealth expansion, and prudent growth investments will be key to achieving sustained profitability and a successful IPO.
Make smarter business decisions with verified insights on companies and directors. Visit Affluense.ai to learn more.
Disclaimer: © 2025. All information is curated from public and third-party sources and provided solely for legitimate business use. Please ensure proper authorization before use.